BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at July 31, 2012
07 August 2012 - 1:45AM
Business Wire
Regulatory News:
BioAlliance Pharma (Paris:BIO)
Pursuant to article L.233-8 II of the Code de commerce (the
French Commercial Code) and article 223-16 of the Règlement
général de l’Autorité des Marchés Financiers (Regulation of the
French stock market authority):
Date Total number of outstanding shares Total number
of voting rights July 31, 2012 17,659,715 Theoretical number of
voting rights: 17,659,715(including treasury shares)
Number of real voting rights:
17,654,204(without treasury shares)
About BioAlliance Pharma
Dedicated to Specialty Pharma and Orphan products in cancer
treatment and in supportive care, with a focus on drug resistance,
BioAlliance conceives and develops innovative products, for
specialty markets especially in the hospital setting and for orphan
or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in
2005, BioAlliance Pharma’s ambition is to become a leading player
in these fields by coupling innovation to patient needs. The
company’s teams have the key competencies required to identify,
develop and register drugs in Europe and USA; the products’
commercialization rights are licensed to international commercial
partners invested in the hospital setting. In areas where medical
needs are insufficiently met, its targeted approaches help overcome
drug resistance and improve patient health & quality of life.
For more information, visit the BioAlliance Pharma web site at
www.bioalliancepharma.com.
Biotest (TG:BIO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biotest (TG:BIO)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Biotest AG (Tradegate (DE)): 0 recent articles
More BioAlliance Pharma News Articles